Skip to main content
main-content
Top

04-15-2019 | Nephropathy | Podcast | Article

Researcher comment: The CREDENCE trial

Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice (6:51).

More content in this series

Related topics

More on this topic